Related Experiment Video
Updated: Jun 28, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Discovery of a novel natural compound, vitekwangin B, with ANO1 protein reduction properties and anticancer potential
Yohan Seo1, Sion Lee1, Minuk Kim2
1New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of Korea.
Abstract:
Background: Prostate cancer and non-small cell lung cancer (NSCLC) present significant challenges in the development of effective therapeutic strategies. Hormone therapies for prostate cancer target androgen receptors and prostate-specific antigen markers. However, treatment options for prostatic small-cell neuroendocrine carcinoma are limited. NSCLC, on the other hand, is primarily treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors but exhibits resistance. This study explored a novel therapeutic approach by investigating the potential anticancer properties of vitekwangin B, a natural compound derived from Vitex trifolia. Methods: Vitekwangin B was chromatographically isolated from the fruits of V. trifolia. ANO1 protein levels in prostate cancer and NSCLC cells were verified and evaluated again after vitekwangin B treatment. Results: Vitekwangin B did not inhibit anoctamin1 (ANO1) channel function but significantly reduced ANO1 protein levels. These results demonstrate that vitekwangin B effectively inhibited cancer cell viability and induced apoptosis in prostate cancer and NSCLC cells. Moreover, it exhibited minimal toxicity to liver cells and did not affect hERG channel activity, making it a promising candidate for further development as an anticancer drug. Conclusion: Vitekwangin B may offer a new direction for cancer therapy by targeting ANO1 protein, potentially improving treatment outcomes in patients with prostate cancer and NSCLC. Further research is needed to explore its full potential and overcome existing drug resistance challenges.
Insights
Vitekwangin B, a natural compound, effectively inhibits prostate cancer and non-small cell lung cancer (NSCLC) cell growth by reducing ANO1 protein levels. This compound shows promise as a novel anticancer therapeutic with minimal toxicity.
Area of Science:
- Natural Product Chemistry
- Oncology
- Pharmacology
Background:
- Prostate cancer and non-small cell lung cancer (NSCLC) pose significant therapeutic challenges.
- Current treatments for prostate cancer and NSCLC face limitations, including drug resistance.
- Prostatic small-cell neuroendocrine carcinoma has limited treatment options.
Purpose of the Study:
- To investigate the anticancer properties of vitekwangin B, a compound isolated from *Vitex trifolia*.
- To explore vitekwangin B as a novel therapeutic agent for prostate cancer and NSCLC.
- To evaluate the effect of vitekwangin B on anoctamin1 (ANO1) protein levels and cancer cell viability.
Main Methods:
- Vitekwangin B was isolated from *Vitex trifolia* fruits using chromatography.
- ANO1 protein levels were assessed in prostate cancer and NSCLC cells before and after vitekwangin B treatment.
- Cancer cell viability and apoptosis were evaluated, along with toxicity to liver cells and hERG channel activity.
Main Results:
- Vitekwangin B significantly reduced ANO1 protein levels in cancer cells.
- Vitekwangin B demonstrated potent inhibition of cancer cell viability and induced apoptosis.
- The compound exhibited minimal toxicity to liver cells and did not affect hERG channel activity.
Conclusions:
- Vitekwangin B shows potential as a novel anticancer drug targeting ANO1 protein.
- This natural compound may offer a new therapeutic strategy for prostate cancer and NSCLC.
- Further research is warranted to fully elucidate vitekwangin B's potential and overcome drug resistance.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

